Integral Diagnostics Ltd (ASX: IDX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Integral Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $984.53 million
P/E Ratio 158.75
Dividend Yield 2.56%
Shares Outstanding 372.93 million
Earnings per share 0.016
Dividend per share 0.07
Year To Date Return N/A
Earnings Yield 0.63%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Integral Diagnostics Ltd (ASX: IDX)
    Latest News

    A man looks surprised as a woman whispers in his ear.
    Broker Notes

    2 ASX shares to buy now at bargain prices that you've forgotten about

    There are many cheap stocks currently out there to consider. Here's a pair you might not have on your radar.

    Read more »

    Two children sit amid a tangle of wires at a desk looking sad and despondent.
    52-Week Lows

    Is opportunity knocking? 2 ASX All Ordinaries shares hitting 52-week lows

    Catch a falling knife? Or opportunity knocking?

    Read more »

    Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
    Earnings Results

    Integral Diagnostics (ASX:IDX) share price on ice after trio of big announcements

    Here's the latest on the ASX diagnostics company amid its half-year results.

    Read more »

    two children squat down in the dirt with gardening tools and a watering can wearing denim overalls and smiling very sweetly.
    Ask a Fund Manager

    2 ASX shares to buy for dirt cheap right now: expert

    Ask A Fund Manager: Forager Funds Management's Gaston Amoros names a pair of stocks that the market is unfairly punishing.

    Read more »

    A surprised and curious male investor drinks black coffee while reading the latest news on rising ASX shares in the newspaper
    Broker Notes

    Here are the latest broker updates from Macquarie. It's not all pretty for ASX shares.

    Macquarie is the latest broker to release its buy and sell tips in early 2022.

    Read more »

    Broker Notes

    Top brokers name 3 ASX shares to buy next week

    Brokers are feeling positive about these ASX shares...

    Read more »

    Thumbs down Facebook icon over dark screen
    Share Fallers

    Why Integral Diagnostics, Mayne Pharma, NEXTDC, & Wesfarmers are dropping

    These ASX shares are ending the week in the red...

    Read more »

    falling healthcare asx share price represented by doctor grimacing at x-ray
    Earnings Results

    Integral Diagnostics (ASX:IDX) share price slides 14% on FY21 earnings

    The market has reacted negatively to Integral Diagnostics' FY21 results.

    Read more »

    share price gaining
    Share Market News

    Which ASX shares are ending the week as the biggest movers today?

    The ASX 300 has spent the day in the red...

    Read more »

    shadow of a man looking out a window with arrows signifying falling share price
    Share Fallers

    Why Chalice Mining, GUD, Integral Diagnostics, & PointsBet are dropping

    These ASX shares are in the red today...

    Read more »

    chart showing an increasing share price
    Dividend Investing

    2 growing ASX dividend shares analysts rate as buys

    These dividend shares are growing at a solid rate...

    Read more »

    busy trader on the phone in front of board depicting asx share price risers and fallers
    Share Market News

    2 All Ords shares this broker rates as buys

    Here's why this leading broker likes these All Ords shares...

    Read more »

    Frequently Asked Questions

    Yes, Integral Diagnostics historically pays two fully franked dividends a year.

    Integral Diagnostics generally pays its shareholder dividends in April and October.

    Integral Diagnostics Ltd listed on the ASX on 21 October 2015.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    29 Aug 2025 $0.0400 100.00% Final 03 Oct 2025
    06 Mar 2025 $0.0250 100.00% Interim 07 Apr 2025
    30 Aug 2024 $0.0330 100.00% Final 03 Oct 2024
    29 Feb 2024 $0.0250 100.00% Interim 02 Apr 2024
    31 Aug 2023 $0.0350 100.00% Final 04 Oct 2023
    02 Mar 2023 $0.0250 100.00% Interim 04 Apr 2023
    01 Sep 2022 $0.0300 100.00% Final 05 Oct 2022
    01 Mar 2022 $0.0400 100.00% Interim 04 Apr 2022
    02 Sep 2021 $0.0700 100.00% Final 06 Oct 2021
    01 Mar 2021 $0.0550 100.00% Interim 06 Apr 2021
    28 Aug 2020 $0.0400 100.00% Final 01 Oct 2020
    28 Feb 2020 $0.0550 100.00% Interim 07 Apr 2020
    30 Aug 2019 $0.0500 100.00% Final 02 Oct 2019
    01 Mar 2019 $0.0500 100.00% Interim 02 Apr 2019
    31 Aug 2018 $0.0400 100.00% Final 04 Oct 2018
    31 Jan 2018 $0.0400 100.00% Interim 05 Mar 2018
    31 Aug 2017 $0.0000 100.00% Final 04 Oct 2017
    28 Feb 2017 $0.0300 100.00% Interim 30 Mar 2017
    31 Aug 2016 $0.0400 100.00% Final 04 Oct 2016

    IDX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Integral Diagnostics Ltd

    Integral Diagnostics Ltd (ASX: IDX) is an Australian healthcare services company providing medical imaging services. 

    The group operates in a single business providing diagnostic imaging to general practitioners, medical specialists, and allied health professionals and their patients. 

    The company operates more than 90 radiology clinics across Australia and New Zealand. It is also a joint venture partner in Medx, expanding its services to the United Kingdom and Ireland.

    IDX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    13 Jan 2026 $2.64 $0.04 1.54% 339,743 $2.57 $2.64 $2.57
    12 Jan 2026 $2.60 $0.06 2.36% 345,855 $2.53 $2.60 $2.52
    09 Jan 2026 $2.54 $-0.01 -0.39% 492,111 $2.53 $2.57 $2.52
    08 Jan 2026 $2.55 $0.04 1.59% 424,631 $2.50 $2.56 $2.48
    07 Jan 2026 $2.51 $0.00 0.00% 491,913 $2.52 $2.52 $2.49
    06 Jan 2026 $2.51 $-0.02 -0.79% 573,933 $2.58 $2.58 $2.49
    05 Jan 2026 $2.53 $0.02 0.80% 387,652 $2.52 $2.57 $2.52
    02 Jan 2026 $2.51 $-0.03 -1.18% 245,418 $2.52 $2.55 $2.51
    31 Dec 2025 $2.54 $0.08 3.25% 553,641 $2.47 $2.55 $2.47
    30 Dec 2025 $2.46 $0.04 1.65% 844,043 $2.42 $2.48 $2.42
    29 Dec 2025 $2.42 $-0.03 -1.22% 436,763 $2.45 $2.46 $2.42
    24 Dec 2025 $2.45 $-0.03 -1.21% 259,506 $2.48 $2.48 $2.42
    23 Dec 2025 $2.48 $0.06 2.48% 763,395 $2.46 $2.49 $2.40
    22 Dec 2025 $2.42 $0.01 0.41% 598,867 $2.46 $2.46 $2.40
    19 Dec 2025 $2.41 $0.00 0.00% 913,323 $2.40 $2.43 $2.38
    18 Dec 2025 $2.41 $-0.05 -2.03% 3,036,855 $2.53 $2.53 $2.30
    17 Dec 2025 $2.46 $-0.02 -0.81% 551,328 $2.47 $2.49 $2.46
    16 Dec 2025 $2.48 $0.02 0.81% 641,547 $2.47 $2.49 $2.45

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    31 Dec 2025 James Hall Buy 6,200 $15,066
    On-market trade.
    22 Dec 2025 Ian Kadish Buy 34,233 $82,843
    Conversion of securities.
    22 Dec 2025 Ian Kadish Exercise 34,233 $82,843
    Conversion of securities. 7,77,919 rights
    16 Dec 2025 Ian Kadish Issued 235,596 $584,278
    Issue of securities. 812,132 Rights
    03 Oct 2025 James Hall Issued 2,652 $7,666
    Dividend Reinvestment Plan (DRP).
    29 Aug 2025 Ian Kadish Exercise 29,072 $84,599
    Conversion of securities. 576,536 Rights
    29 Aug 2025 Ian Kadish Issued 29,072 $84,599
    Conversion of securities.
    28 Aug 2025 Ian Kadish Expiry 398,962 $1,172,948
    As advised by the company. Lapse of rights. 605,608 rights
    07 Apr 2025 James Hall Issued 2,088 $4,738
    Dividend Reinvestment Plan (DRP).
    11 Mar 2025 Raelene Murphy Buy 15,000 $35,400
    On-market trade.
    05 Mar 2025 Ian Kadish Buy 25,000 $53,950
    On-market trade.
    04 Mar 2025 James Hall Buy 36,000 $78,840
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Andrew James Fay Non-Executive Director Jul 2022
    Mr Fay brings to the Board over 30 years of experience in funds and investment management, including Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management (Australia) Limited. He also held a number of other senior investment roles at Deutsche Asset Management and previously at AMP Capital. He was a member of the Investment Board Committee of the Financial Services Council. Andrew is an experienced company director across ASX-listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, executive remuneration frameworks, strategy, investment and corporate governance. Specifically, he has sector experience and expertise in financial services, including investment, funds, property and infrastructure management. He is Chair of the People, Culture Committee.
    Ms Raelene Margaret Murphy Non-Executive Director Oct 2017
    Ms Murphy, beginning her career in audit, has over 30 years of experience in strategic, financial and operational leadership in both industry and professional advisory. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career, she specialised in operational and financial restructuring, with a particular emphasis on merger and acquisition integration across a range of significant public and private companies. She is Member of the Risk, Compliance and Sustainability Committee and Member of the People, Culture Committee.
    Ms Ingrid Anne Player Non-Executive Director Aug 2023
    Ms Player is an experienced former Executive and Non Executive Director with international commercial and regulatory experience in mergers and acquisitions, corporate governance, capital developments, risk and sustainability that spans different markets and industries in Australia and Europe. Her experience includes her senior executive roles with one of Australias leading healthcare providers, where she worked closely with the Board to deliver various capital raisings, retail listed notes, and debt finance deals. Her roles included Group Executive for Legal, Governance and Sustainability as well as General Counsel and Company Secretary. She is Chair of the Risk, Compliance and Sustainability Committee and Member of the People, Culture Committee.
    Mr James Tobias Hall Non-Executive DirectorNon-Executive Chairman Sep 2023
    Mr Hall healthcare executive leadership experience in Australia and New Zealand and is an experienced Board and Committee Chair. He was the Group CEO of St Vincents Health Australia, the second largest non government provider of hospital and care services in the country. He has also overseen multi site, for profit generating businesses at both board and executive levels in employment services, early learning services and aged care. He also has involvement in policy development at a federal level in Australia, having served on committees established by Prime Ministers, Deputy Prime Ministers, Health Ministers, Employment and Social Services Ministers. He is currently Non Executive Chair of For Purpose Aged Care, Non Executive Director of UNICEF Australia, a Director of Papua New Guinea Sustainable Development Fund and a trustee of Yajilarra. He is Member of the People, Culture Committee.
    Dr Ian Kadish Chief Executive OfficerManaging Director May 2017
    Dr Kadish began his career as a medical doctor in Johannesburg, South Africa. He followed with several roles overseas including McKinsey and Company, CSC Healthcare in New York City, and Netcare, a major hospital group in South Africa and the United Kingdom, where he was an Executive Director. His roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group and CEO of Laverty Pathology. He is Director of the Australian Diagnostic Imaging Association (ADIA). He is Member of the Integral Clinical Leadership Committee.
    Ms Laura Nicole McBain Non-Executive Director Dec 2024
    Ms McBain had been a Non Executive Director of Capitol. She is an experienced Executive and Non Executive Director with a strong background in the food, beverage, and consumer industries, specialising in brand development, fast growth, corporate governance, financial oversight, and business development. Her experience includes senior leadership roles as Managing Director at Bellamys Australia Limited and Maggie Beer Holdings Limited. She currently serves as a Non Executive Director at Tasmanian Irrigation Pty Ltd and the Tasmanian Devils AFL Club and is also a Director of the Australia China Business Council and President of its Tasmania Branch. In recognition of her leadership and contributions, she was named the 2013 Telstra Tasmanian Businesswoman of the Year and the Telstra Australian Businesswoman of the Year. She is Member of the Risk, Compliance and Sustainability Committee.
    Dr Kevin (Kai-Chung) Shaw Non-Executive Director Dec 2024
    Dr Shaw had been a Non Executive Director of Capitol. He has sub specialty training in neuroradiology and musculoskeletal imaging. He is the current Director of Medical Imaging at Barwon Health. He is also a Clinical Professor at Deakin Medical School. He is a past examiner for the Royal Australian and New Zealand College of Radiologists (RANZCR) and previously sat on the Colleges Anatomy Exam Review Panel. He has been an MRI Clinical Reviewer for the College since 2014. Kevin currently sits on the Medical Advisory Committee, Technology/Clinical Practice Committee, and Mortality Committee at Barwon Health, as well as the Medical Imaging Advisory Board at Deakin University. He is a councilor for Australian Medical Association Victoria as the State Representative for RANZCR. He is Member of the Risk, Compliance and Sustainability Committee and Member of the People, Culture Committee.
    Mr Manish Mittal Non-Executive Director Feb 2025
    Dr Mittal has a professional focus on MRI, including musculoskeletal, prostrate and cardiac imaging in addition to experience in neuroradiology and abdominal radiology. He also has experience in hospital settings including emergencies and trauma. He has held teaching roles at Melbourne University & Deakin University. He has worked within IDX and its precursor businesses for over 18 years and held senior clinical governance and leadership roles across a number of IDX business units which have enabled him to develop a deep understanding of the IDX operating businesses. He is Member of the Risk, Compliance and Sustainability Committee.
    Mr John J Merity Company Secretary Jun 2024
    -
    Craig White Chief Financial Officer
    -
    John J Merity Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 76,697,943 20.59%
    Citicorp Nominees Pty Limited 70,835,402 19.02%
    J P Morgan Nominees Australia Pty Limited 64,194,143 17.24%
    Washington H Soul Pattinson and Company Limited 10,632,490 2.85%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/c> 9,070,392 2.44%
    HSBC Custody Nominees (Australia) Limited A/C 2 6,499,188 1.75%
    BNP Paribas Nominees Pty Ltd <HUB24 Custodial Serv Ltd> 5,869,917 1.58%
    UBS Nominees Pty Ltd 5,066,697 1.36%
    HSBC Custody Nominees (Australia) Limited <NT Comnwlth Super Corp A/c> 3,688,396 0.99%
    Kim New Holdings Pty Ltd 3,389,045 0.91%
    BNP Paribas Noms (NZ) Ltd 3,131,792 0.84%
    Lethean Holdings Pty Ltd <Howitt No 8 A/c> 2,944,760 0.79%
    Idinoc Pty Ltd <J & R Conidi Family A/c> 2,502,713 0.67%
    Firbar Pty Ltd <The Howitt No 4 A/c> 2,357,230 0.63%
    J A Mullins Pty Ltd <James Mullins Family A/c> 2,316,051 0.62%
    Masfen Securities Limited 2,250,000 0.60%
    Mittal Holdings Pty Ltd <Howitt No 12 A/c> 2,085,907 0.56%
    A & S French Pty Ltd <The A J French Family A/c> 1,797,915 0.48%
    Wyndham Salter Pty Ltd <The Howitt No 10 A/c> 1,792,947 0.48%
    BNP Paribas Noms Pty Ltd 1,622,012 0.44%

    Profile

    since

    Note